|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Waggoner SE: Cervical cancer. Lancet.
361:2217–2225. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen J, Shi D, Liu X, Fang S, Zhang J and
Zhao Y: Targeting SPARC by lentivirus-mediated RNA interference
inhibits cervical cancer cell growth and metastasis. BMC Cancer.
12:4642012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rao Y, Wang H, Fan L and Chen G: Silencing
MTA1 by RNAi reverses adhesion, migration and invasiveness of
cervical cancer cells (SiHa) via altered expression of p53, and
E-cadherin/β-catenin complex. J Huazhong Univ Sci Technolog Med
Sci. 31:1–9. 2011.PubMed/NCBI
|
|
5
|
Li Y, Wang W, Wang W, et al: Correlation
of TWIST2 up-regulation and epithelial-mesenchymal transition
during tumorigenesis and progression of cervical carcinoma. Gynecol
Oncol. 124:112–118. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
de Vega S, Iwamoto T and Yamada Y:
Fibulins: multiple roles in matrix structures and tissue functions.
Cell Mol Life Sci. 66:1890–1902. 2009.PubMed/NCBI
|
|
7
|
Gallagher WM, Currid CA and Whelan LC:
Fibulins and cancer: friend or foe? Trends Mol Med. 11:336–340.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Law EW, Cheung AK, Kashuba VI, et al:
Anti-angiogenic and tumor-suppressive roles of candidate
tumor-suppressor gene, Fibulin-2, in nasopharyngeal carcinoma.
Oncogene. 31:728–738. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yi CH, Smith DJ, West WW and Hollingsworth
MA: Loss of fibulin-2 expression is associated with breast cancer
progression. Am J Pathol. 170:1535–1545. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schluterman MK, Chapman SL, Korpanty G,
Ozumi K, Fukai T, Yanagisawa H and Brekken RA: Loss of fibulin-5
binding to beta1 integrins inhibits tumor growth by increasing the
level of ROS. Dis Model Mech. 3:333–342. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hu Z, Ai Q, Xu H, et al: Fibulin-5 is
down-regulated in urothelial carcinoma of bladder and inhibits
growth and invasion of human bladder cancer cell line 5637. Urol
Oncol. 29:430–435. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yue W, Sun Q, Landreneau R, Wu C,
Siegfried JM, Yu J and Zhang L: Fibulin-5 suppresses lung cancer
invasion by inhibiting matrix metalloproteinase-7 expression.
Cancer Res. 69:6339–6346. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Moll F, Katsaros D, Lazennec G, et al:
Estrogen induction and overexpression of fibulin-1C mRNA in ovarian
cancer cells. Oncogene. 21:1097–1107. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Greene LM, Twal WO, Duffy MJ, et al:
Elevated expression and altered processing of fibulin-1 protein in
human breast cancer. Br J Cancer. 88:871–878. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bardin A, Moll F, Margueron R, et al:
Transcriptional and posttranscriptional regulation of fibulin-1 by
estrogens leads to differential induction of messenger ribonucleic
acid variants in ovarian and breast cancer cells. Endocrinology.
146:760–768. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Seeliger H, Camaj P, Ischenko I, et al:
EFEMP1 expression promotes in vivo tumor growth in human pancreatic
adenocarcinoma. Mol Cancer Res. 7:189–198. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Song EL, Hou YP, Yu SP, et al: EFEMP1
expression promotes angiogenesis and accelerates the growth of
cervical cancer in vivo. Gynecol Oncol. 121:174–180. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Song EL, Chen SG and Wang HQ: The
expression of EFEMP1 in cervical carcinoma and its relationship
with prognosis. Gynecol Oncol. 117:417–422. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hu B, Thirtamara-Rajamani KK, Sim H and
Viapiano MS: Fibulin-3 is uniquely upregulated in malignant gliomas
and promotes tumor cell motility and invasion. Mol Cancer Res.
7:1756–1770. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kanda M, Nomoto S, Okamura Y, Hayashi M,
Hishida M, Fujii T, Nishikawa Y, Sugimoto H, Takeda S and Nakao A:
Promoter hypermethylation of fibulin 1 gene is associated with
tumor progression in hepatocellular carcinoma. Mol Carcinog.
50:571–579. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cheng YY, Jin H, Liu X, et al: Fibulin 1
is downregulated through promoter hypermethylation in gastric
cancer. Br J Cancer. 99:2083–2087. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wlazlinski A, Engers R, Hoffmann MJ, et
al: Downregulation of several fibulin genes in prostate cancer.
Prostate. 67:1770–1780. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xie L, Palmsten K, MacDonald B, et al:
Basement membrane derived fibulin-1 and fibulin-5 function as
angiogenesis inhibitors and suppress tumor growth. Exp Biol Med.
233:155–162. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hwang CF, Chien CY, Huang SC, et al:
Fibulin-3 is associated with tumour progression and a poor
prognosis in nasopharyngeal carcinomas and inhibits cell migration
and invasion via suppressed AKT activity. J Pathol. 222:367–379.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sadr-Nabavi A, Ramser J, Volkmann J, et
al: Decreased expression of angiogenesis antagonist EFEMP1 in
sporadic breast cancer is caused by aberrant promoter methylation
and points to an impact of EFEMP1 as molecular biomarker. Int J
Cancer. 124:1727–1735. 2009. View Article : Google Scholar
|
|
26
|
Hu Y, Pioli PD, Siegel E, et al: EFEMP1
suppresses malignant glioma growth and exerts its action within the
tumor extracellular compartment. Mol Cancer. 10:1232011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim EJ, Lee SY, Woo MK, et al: Fibulin-3
promoter methylation alters the invasive behavior of non-small cell
lung cancer cell lines via MMP-7 and MMP-2 regulation. Int J Oncol.
40:402–408. 2012.PubMed/NCBI
|
|
28
|
Chen L, Sun B, Zhang S, et al: Influence
of microenvironments on microcirculation patterns and tumor
invasion-related protein expression in melanoma. Oncol Rep.
21:917–923. 2009.PubMed/NCBI
|
|
29
|
Argraves WS, Greene LM, Cooley MA and
Gallagher WM: Fibulins: physiological and disease perspectives.
EMBO Rep. 4:1127–1131. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Berk DR, Bentley DD, Bayliss SJ, Lind A
and Urban Z: Cutis laxa: a review. J Am Acad Dermatol.
66:842.e1–17. 2012.PubMed/NCBI
|
|
31
|
Huang J, Yamashiro Y, Papke CL, et al:
Angiotensin-converting enzyme-induced activation of local
angiotensin signaling is required for ascending aortic aneurysms in
fibulin-4-deficient mice. Sci Transl Med. 5:183ra581–11.
2013.PubMed/NCBI
|
|
32
|
Xiang Y, Sekine T, Nakamura H, et al:
Fibulin-4 is a target of autoimmunity predominantly in patients
with osteoarthritis. J Immunol. 176:3196–3204. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gallagher WM, Greene LM, Ryan MP, Sierra
V, Berger A, Laurent-Puig P and Conseiller E: Human fibulin-4:
analysis of its biosynthetic processing and mRNA expression in
normal and tumour tissues. FEBS Lett. 489:59–66. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ying J, Shan L, Li J, et al: Genome-wide
screening for genetic alterations in esophageal cancer by aCGH
identifies 11q13 amplification oncogenes associated with nodal
metastasis. PLoS One. 7:e397972012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ormandy CJ, Musgrove EA, Hui R, Daly RJ
and Sutherland RL: Cyclin D1, EMS1 and 11q13 amplification in
breast cancer. Breast Cancer Res Treat. 78:323–335. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Soumaoro LT, Uetake H, Higuchi T, Takagi
Y, Enomoto M and Sugihara K: Cyclooxygenase-2 expression: a
significant prognostic indicator for patients with colorectal
cancer. Clin Cancer Res. 10:8465–8471. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Weidner N, Folkman J, Pozza F, et al:
Tumor angiogenesis: a new significant and independent prognostic
indicator in early-stage breast carcinoma. J Natl Cancer Inst.
84:1875–1887. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Landis JR and Koch GG: The measurement of
observer agreement for categorical data. Biometrics. 33:159–174.
1977. View
Article : Google Scholar : PubMed/NCBI
|
|
39
|
McLaughlin PJ, Chen Q, Horiguchi M, et al:
Targeted disruption of fibulin-4 abolishes elastogenesis and causes
perinatal lethality in mice. Mol Cell Biol. 26:1700–1709. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Weis SM and Cheresh DA: Tumor
angiogenesis: molecular pathways and therapeutic targets. Nat Med.
17:1359–1370. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yanagisawa H, Schluterman MK and Brekken
RA: Fibulin-5, an integrin-binding matricellular protein: its
function in development and disease. J Cell Commun Signal.
3:337–347. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Albig AR, Neil JR and Schiemann WP:
Fibulins 3 and 5 antagonize tumor angiogenesis in vivo. Cancer Res.
66:2621–2629. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Henrotin Y, Gharbi M, Mazzucchelli G,
Dubuc JE, De Pauw E and Deberg M: Fibulin 3 peptides Fib3-1 and
Fib3-2 are potential biomarkers of osteoarthritis. Arthritis Rheum.
64:2260–2267. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Pass HI, Levin SM, Harbut MR, et al:
Fibulin-3 as a blood and effusion biomarker for pleural
mesothelioma. N Engl J Med. 367:1417–1427. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Piura E and Piura B: Autoantibodies to
tumor-associated antigens in breast carcinoma. J Oncol.
2010:2649262010. View Article : Google Scholar : PubMed/NCBI
|
